Cryolife Inc (NYSE:CRY) Director C Elkins Ronald sold 1,000 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00. Following the sale, the director now owns 99,849 shares in the company, valued at $1,996,980. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
C Elkins Ronald also recently made the following trade(s):
- On Monday, November 6th, C Elkins Ronald sold 1,000 shares of Cryolife stock. The shares were sold at an average price of $19.03, for a total transaction of $19,030.00.
Cryolife Inc (NYSE CRY) opened at $18.65 on Friday. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. Cryolife Inc has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The stock has a market cap of $630.67, a P/E ratio of 66.61 and a beta of 0.82.
Cryolife (NYSE:CRY) last released its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. During the same quarter last year, the business earned $0.13 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. sell-side analysts forecast that Cryolife Inc will post 0.28 earnings per share for the current year.
CRY has been the subject of a number of research reports. Lake Street Capital raised their price objective on shares of Cryolife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. TheStreet lowered shares of Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research lowered shares of Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Cryolife presently has an average rating of “Hold” and an average price target of $23.63.
Several hedge funds have recently made changes to their positions in CRY. Russell Investments Group Ltd. acquired a new stake in shares of Cryolife during the 3rd quarter worth approximately $6,164,000. William Blair Investment Management LLC acquired a new stake in shares of Cryolife during the 2nd quarter worth approximately $4,517,000. Macquarie Group Ltd. grew its position in shares of Cryolife by 16.0% during the 3rd quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock worth $36,531,000 after buying an additional 221,574 shares during the period. Thomson Horstmann & Bryant Inc. grew its position in shares of Cryolife by 139.0% during the 3rd quarter. Thomson Horstmann & Bryant Inc. now owns 224,518 shares of the medical equipment provider’s stock worth $5,096,000 after buying an additional 130,593 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Cryolife by 6.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after buying an additional 110,973 shares during the period. 73.28% of the stock is owned by institutional investors.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.